Contract facts
NONENo full NAICS 541990 intel page yet. Browse NAICS intelligence
CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL is a federal NONE award for Fda Office Of Acq Grant Svcs held by American College of Medical Toxicology, Inc. Estimated value $2.7M ($2.7M obligated). Current period of performance ends Sep 29, 2026. Last award drew 1 bidder. Place of performance: SILVER SPRING MD.
CHARACTERIZE NALOXONES CLINICAL USE, RISKS, BENEFITS, AND EFFECTIVENESS FOR REVERSING OPIOID OVERDOSES IN PRE-HOSPITAL SETTINGS. USING QUALITATIVE AND QUANTITATIVE BLOOD TOXICOLOGY TESTS, DETERMINE THE RISKS, BENEFITS, EFFECTIVENESS OF HIGH DOSE NAL
Recompete timing
PublicCurrent PoP ends Sep 29, 2026 (22 days remaining). Agencies typically plan 12–18 months ahead — at 0.7 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordAmerican College of Medical Toxicology, Inc — $6.2M obligated across 10 awards (firm-wide, all agencies).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40123C00184?
75F40123C00184 (Characterize naloxones clinical USE RISKS) is a Fda Office Of Acq Grant Svcs award with a potential value of $2.7M, currently held by American College of Medical Toxicology, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40123C00184?
Fda Office Of Acq Grant Svcs awarded 75F40123C00184 to American College of Medical Toxicology, Inc (potential $2.7M).
Who is the incumbent on 75F40123C00184?
American College of Medical Toxicology, Inc is the incumbent with $6.2M across 10 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2026.
When does American College of Medical Toxicology, Inc’s 75F40123C00184 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Seen enough? Run one full capture cycle on 75F40123C00184 — $90 for 90 days.
This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.
$1/day · one payment · no subscription
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.